MIL62 not checked
Beijing Mabworks Biotech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Phase 1b: Participants will receive intravenous (IV) infusions of MIL62 at doses of 500 mg or 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, W79D1, W105D1, W131D1, W157D1, W183D1, and W209D1. Participants initially assigned to the 500 mg dose group who exhibit good tolerance may be escalated to the 1000 mg dose starting from W25D1. Phase 3 (Randomised Controlled Period \[RCP\]):…”In the company’s words, NCT05314010 on ClinicalTrials.gov
- Main trialPhase 3
- “This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.”In the company’s words, NCT05314010 on ClinicalTrials.gov
Other drugs for Neuromyelitis Optica Spectrum Disorder
- EculizumabAlexion Pharmaceuticals, Inc. · Phase 3
- SatralizumabRoche · Phase 3
- B001Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- RavulizumabAlexion Pharmaceuticals, Inc. · Phase 3
- DivozilimabBiocad · Phase 3
- CTX112CRISPR Therapeutics · Phase 1/2
Coming up1
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 21 Feb 2025 | A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) | |
| Phase 3Recruiting | Dec 2028 | A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus | |
| Phase 1/2Active, not recruiting | 16 Jan 2025 | Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis | |
| Phase 3Unknown | Mar 2025 | MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma | |
| Phase 3Unknown | 13 May 2025 | A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy | |
| Phase 2Completed | 21 Nov 2024 | A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus | |
| Phase 1/2Unknown | 9 Jan 2024 | MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) | |
| Phase 1/2Completed | 4 Mar 2025 | A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy | |
| Phase 1Completed | 30 May 2019 | A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026